<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673933</url>
  </required_header>
  <id_info>
    <org_study_id>PC TA203/08</org_study_id>
    <nct_id>NCT00673933</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris</brief_title>
  <official_title>A Blinded, Randomized, Intra-individual, Vehicle-controlled and Multi-centre Study of Photodynamic Therapy With MAL Cream in Patients With Skin Type V or VI With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicenter study, patients with dark skin and acne vulgaris will be included. The
      patients will receive treatment with MAL PDT and placebo PDT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment period started within 2 weeks of the study screen. Patients received two
      treatments (MAL PDT and vehicle PDT) to each of the treatment areas, 2 weeks apart, and were
      followed-up 4 weeks after last treatment. The total duration of the study was 6-8 weeks.

      Methyl aminolevulinate 80 mg/g cream (MAL cream 8%)and vehicle was applied for 1.5 hours
      before illumination (AktiliteÂ® CL128), total light dose 37 J/cm2
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment</measure>
    <time_frame>4 weeks after last treatment, 6 weeks after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema Score (Mild and Moderate)Immediately After First PDT</measure>
    <time_frame>Immediately after treatment at baseline</time_frame>
    <description>Patients with mild or moderate erythema after first treatment at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Lesion Counts From Baseline</measure>
    <time_frame>4 weeks after last treatment, 6 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Noninflammatory Lesion Counts From Baseline</measure>
    <time_frame>4 weeks after last treatment, 6 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Score (Mild and Moderate)Immediately After Second Treatment</measure>
    <time_frame>Immediately after second treatment, 2 weeks after baseline</time_frame>
    <description>Patients with mild or moderate erythema after second treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Score (Mild and Moderate)1 Day After First Treatment</measure>
    <time_frame>1 day after 1st treatment and baseline</time_frame>
    <description>Patients with mild or moderate erythema 1 day after first treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDT using MAL crem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PDT using Placebo cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl aminolevulinate (MAL) PDT</intervention_name>
    <description>Cream application followed by illumination with red light</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female and male patients, age 15 to 40 years with acne vulgaris.

          2. Patients with skin type V or VI (Fitzpatrick).

          3. Patients with two areas of each 8x8 cm2 on the back that include at least 5
             inflammatory lesions (papules, pustules, and nodules) each. The minimum distance
             between the two areas should be at least 4 cm.

          4. Patients with no more than 2 nodular lesions in any of the two areas of each 8x8 cm2
             on the back.

          5. Patients who are surgically sterile, postmenopausal, abstinent, or willing to use an
             adequate means of contraception including birth control pills, or barrier methods and
             spermicide for at least 14 days prior to Day 0. Patients using birth control pills
             must have used the same product and dose for at least 3 months and must agree to stay
             with the same product and dose for an additional 3 months.

          6. Patients must be willing and capable of following study instructions to the extent and
             degree required by the protocol.

          7. Patients must sign the approved informed consent form prior to any study procedures.

          8. Patients must be willing to be photographed. Patients must be willing to sign a
             photography consent form.

        Exclusion Criteria:

          1. Known allergy to MAL, to a similar PDT compound, or to excipients of the cream.

          2. Participation in other clinical studies either concurrently or within the last 30
             days.

          3. Patients who have a condition or who are in a situation, which, in the investigator's
             opinion, may put the patient at risk, may confound the study results, or may interfere
             with the patient's participation in the study.

          4. Clinically significant sensitivity to visible light, or has porphyria or porphyrin
             sensitivity.

          5. Exposure to ultraviolet radiation (UVB phototherapy) within the last 30 days.

          6. Patients with a washout period for topical treatments for their acne in the two
             treatment areas of less than 14 days. Any topical treatment on the face or other areas
             outside the two treatment areas will be allowed.

          7. Patients with a washout period for oral antibiotics for treatment of their acne of
             less than 1 month.

          8. Patients with a washout period for oral isotretinoin of less than 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish C Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Institute of DuPage Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>July 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2013</results_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two areas on the back per patient was treated, one area with Visonac and one with vehicle</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Visonac Cream With PDT and Vehicle and PDT</title>
          <description>Two areas on the back per patient was treated, one area with Visonac and one with vehicle. Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Visonac and Vehicle Cream With PDT</title>
          <description>Two areas on the back per patient was treated, one area with Visonac (Methyl aminolevulinate) and one with vehicle followed by red light illumination.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin type</title>
          <description>Skin type according to the Fitzpatrick Classification Scale. Skin type V: Brown, dark brown.Very rarely burns, tans very easily Skin type VI: Black, very dark brown to black. Never burns, tans very easily, deeply pigmented</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Skin type V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory lesions</title>
          <units>lesion</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Visonac treated area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" lower_limit="5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vehicle treated area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non inflammatory lesions</title>
          <units>Lesion</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Visonac treated area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vehicle treated area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" lower_limit="2" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment</title>
        <time_frame>4 weeks after last treatment, 6 weeks after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>PDT using MAL cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>PDT using Placebo cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Score (Mild and Moderate)Immediately After First PDT</title>
        <description>Patients with mild or moderate erythema after first treatment at baseline.</description>
        <time_frame>Immediately after treatment at baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>PDT using MAL cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>PDT using Placebo cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Score (Mild and Moderate)Immediately After First PDT</title>
          <description>Patients with mild or moderate erythema after first treatment at baseline.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Lesion Counts From Baseline</title>
        <time_frame>4 weeks after last treatment, 6 weeks after baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>PDT using MAL cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>PDT using Placebo cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Lesion Counts From Baseline</title>
          <population>ITT</population>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.70" spread="2.43"/>
                    <measurement group_id="O2" value="-3.90" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Noninflammatory Lesion Counts From Baseline</title>
        <time_frame>4 weeks after last treatment, 6 weeks after baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>PDT using MAL cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>PDT using Placebo cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Noninflammatory Lesion Counts From Baseline</title>
          <population>ITT</population>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="4.84"/>
                    <measurement group_id="O2" value="-2.50" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Score (Mild and Moderate)Immediately After Second Treatment</title>
        <description>Patients with mild or moderate erythema after second treatment.</description>
        <time_frame>Immediately after second treatment, 2 weeks after baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>PDT using MAL cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>PDT using Placebo cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Score (Mild and Moderate)Immediately After Second Treatment</title>
          <description>Patients with mild or moderate erythema after second treatment.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Score (Mild and Moderate)1 Day After First Treatment</title>
        <description>Patients with mild or moderate erythema 1 day after first treatment.</description>
        <time_frame>1 day after 1st treatment and baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>PDT using MAL cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>PDT using Placebo cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Score (Mild and Moderate)1 Day After First Treatment</title>
          <description>Patients with mild or moderate erythema 1 day after first treatment.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Visonac Cream With PDT</title>
          <description>PDT using MAL cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Cream With PDT</title>
          <description>PDT using Placebo cream
Methyl aminolevulinate (MAL) PDT : Cream application followed by illumination with red light</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus nos</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin warm</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma Nos</sub_title>
                <description>Non treatment site, included under both Visonac and vehicle arm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Ashish Bhatia</name_or_title>
      <organization>Dermatology Institute</organization>
      <phone>630-942-5040</phone>
      <email>acbhatia@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

